Nothing Special   »   [go: up one dir, main page]

AR077451A1 - Utilizacion de benzidamina en el tratamiento de enfermedades dependientes de p40 - Google Patents

Utilizacion de benzidamina en el tratamiento de enfermedades dependientes de p40

Info

Publication number
AR077451A1
AR077451A1 ARP100102406A ARP100102406A AR077451A1 AR 077451 A1 AR077451 A1 AR 077451A1 AR P100102406 A ARP100102406 A AR P100102406A AR P100102406 A ARP100102406 A AR P100102406A AR 077451 A1 AR077451 A1 AR 077451A1
Authority
AR
Argentina
Prior art keywords
benzidamine
treatment
dependent diseases
psoriasis
overexpression
Prior art date
Application number
ARP100102406A
Other languages
English (en)
Inventor
Angelo Guglielmotti
Giuseppe Biondi
Giorgina Mangano
Original Assignee
A F S P A Aziende Chimiche Riunite Angelini Francesco A C R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A F S P A Aziende Chimiche Riunite Angelini Francesco A C R filed Critical A F S P A Aziende Chimiche Riunite Angelini Francesco A C R
Publication of AR077451A1 publication Critical patent/AR077451A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilizacion de benzidamina en el tratamiento de enfermedades inflamatorias, en particular la enfermedad de Crohn, la artritis reumática, la psoriasis artrítica y la psoriasis, provocadas por la expresion o la sobreexpresion de la subunidad p40 de las citocinas. Reivindicacion 4: Utilizacion segun la reivindicacion 3, en la que dicho medicamento para la administracion sistémica comprende una cantidad comprendida entre 1 mg y 100 mg, más preferentemente entre 5 mg y 50 mg de benzidamina o sales de adicion de ácido fisiologicamente aceptables de la misma, expresada como base libre.
ARP100102406A 2009-07-08 2010-07-06 Utilizacion de benzidamina en el tratamiento de enfermedades dependientes de p40 AR077451A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09425270 2009-07-08

Publications (1)

Publication Number Publication Date
AR077451A1 true AR077451A1 (es) 2011-08-31

Family

ID=41279454

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102406A AR077451A1 (es) 2009-07-08 2010-07-06 Utilizacion de benzidamina en el tratamiento de enfermedades dependientes de p40

Country Status (26)

Country Link
US (1) US20120302618A1 (es)
EP (1) EP2451452B1 (es)
JP (1) JP5753843B2 (es)
KR (1) KR101723996B1 (es)
CN (1) CN102470125B (es)
AR (1) AR077451A1 (es)
AU (1) AU2010270425B2 (es)
BR (1) BR112012000410B8 (es)
CA (1) CA2760176C (es)
CY (1) CY1116914T1 (es)
DK (1) DK2451452T3 (es)
EA (1) EA022862B1 (es)
ES (1) ES2554332T3 (es)
GE (1) GEP20146156B (es)
HK (1) HK1165280A1 (es)
HR (1) HRP20151393T8 (es)
HU (1) HUE028220T2 (es)
IL (1) IL216717A (es)
MX (1) MX2012000498A (es)
PL (1) PL2451452T3 (es)
PT (1) PT2451452E (es)
SG (2) SG176686A1 (es)
SI (1) SI2451452T1 (es)
SM (1) SMT201500277B (es)
UA (1) UA105666C2 (es)
WO (1) WO2011003737A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107873024A (zh) * 2015-02-09 2018-04-03 塞尔利克斯生物私人有限公司 用于治疗粘膜炎的组合物和方法
US20180244792A1 (en) * 2015-09-10 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
DK3481370T3 (da) * 2016-07-08 2021-06-07 Acraf Farmaceutisk sammensætning omfattende benzydamin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (es) 1963-08-09
IT1184123B (it) 1985-01-22 1987-10-22 Acraf Impiego della benzidamina nel trattamento delle infezioni da trichomonas vaginalis e gardnerella vaginalis
IT1276040B1 (it) * 1993-07-27 1997-10-24 Angelini Francesco Ist Ricerca Uso della benzidamina nel trattamento di stati patologici causati dal tnf
IT1274026B (it) 1994-03-01 1997-07-14 Acraf Composizione antitosse
IT1274655B (it) 1995-02-28 1997-07-18 Smithkline Beecham Farma Composizioni farmaceutiche contenenti un agente antiinfiammatorio e un agente antimicrobico
SI1845942T1 (sl) * 2005-01-14 2014-06-30 Camurus Ab Gnrh analogne formulacije
EP1845942B1 (en) * 2005-01-14 2014-04-09 Camurus Ab Gnrh analogue formulations
GB0604824D0 (en) * 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders

Also Published As

Publication number Publication date
BR112012000410A2 (pt) 2016-04-05
EA201270143A1 (ru) 2012-06-29
ES2554332T3 (es) 2015-12-18
HRP20151393T8 (hr) 2016-07-01
KR20120052201A (ko) 2012-05-23
GEP20146156B (en) 2014-09-10
PT2451452E (pt) 2016-01-14
DK2451452T3 (en) 2015-11-23
EP2451452B1 (en) 2015-10-07
CY1116914T1 (el) 2017-04-05
SI2451452T1 (sl) 2015-12-31
JP2012532173A (ja) 2012-12-13
SMT201500277B (it) 2016-01-08
IL216717A (en) 2017-06-29
BR112012000410B8 (pt) 2020-12-08
HRP20151393T1 (hr) 2016-01-15
EP2451452A1 (en) 2012-05-16
SG176686A1 (en) 2012-01-30
CA2760176C (en) 2017-01-03
CA2760176A1 (en) 2011-01-13
PL2451452T3 (pl) 2016-03-31
IL216717A0 (en) 2012-02-29
EA022862B1 (ru) 2016-03-31
JP5753843B2 (ja) 2015-07-22
BR112012000410B1 (pt) 2019-12-31
MX2012000498A (es) 2012-04-30
UA105666C2 (uk) 2014-06-10
CN102470125B (zh) 2015-08-19
CN102470125A (zh) 2012-05-23
KR101723996B1 (ko) 2017-04-06
AU2010270425A1 (en) 2011-12-22
HUE028220T2 (en) 2016-12-28
WO2011003737A1 (en) 2011-01-13
SG10201403088XA (en) 2014-10-30
HK1165280A1 (zh) 2012-11-23
US20120302618A1 (en) 2012-11-29
AU2010270425B2 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR084691A1 (es) Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
ECSP034571A (es) Nuevas composiciones de medicamentos a base de sales de tiotropio y sales del salmeterol
CO6480932A2 (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
ECSP11011235A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
ECSP10010553A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
DK2244703T3 (da) Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier
BR112014009242A2 (pt) nanossuspensão farmacêutica
ECSP077843A (es) Tratamiento o prevención del prurito
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
AR077451A1 (es) Utilizacion de benzidamina en el tratamiento de enfermedades dependientes de p40
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
NI201000181A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona.
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
AR076832A1 (es) Derivados de 1- amino-alquilciclohexano para el tratamiento de enfermedades inflamatorias de la piel
BR112015010808A2 (pt) pastilha medicamentosa à base de ibuprofeno sódico di-hidratado
CO6592037A2 (es) Combinación de un aine y un aminoacido
AR084435A1 (es) Combinacion y composicion para el tratamiento de obesidad
CL2008003584A1 (es) Uso de la 10-[(3r)-1-azabiciclo]oct-3-ilmetil]-10-h-fenotiazina, o una de sus sales farmaceuticamente aceptables para la preparación de un medicamento util para prevenir o tratar la bronconeumopatia obstructiva.

Legal Events

Date Code Title Description
FC Refusal